{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:19:48Z","timestamp":1788380388505,"version":"build-2803163510"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Selective histone deacetylase (HDAC) inhibition has recently emerged as a promising strategy for antitumor targeted therapy. HDAC6 is a member of the HDAC family that mainly deacetylates non-histone proteins, regulating multiple cellular functions, including lipogenesis. HDAC6 is associated with the development and progression of colorectal cancer (CRC) and is related to CRC poor prognosis. This paper evaluates the effects of the selective HDAC6 inhibitor ITF3756 in CRC cells in combination with bortezomib (BTZ), a proteasome inhibitor that promotes lipogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Cell viability was evaluated by MTT assay. Lipid content and quantification were estimated by ORO staining and triacylglycerol spectrophotometric kit. Apoptosis was detected by Annexin V\/PI and cell cycle distribution analysis. Western blot was used to detect proteins involved in lipogenesis and apoptosis. SREBP-1 was knocked down by a specific siRNA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The selective HDAC6 inhibitor ITF3756 reduced the viability of HCT116 and HT29 colon cancer cells and promoted lipogenesis. Considering the involvement of HDAC6 in controlling lipid metabolism, ITF3756 was combined with bortezomib (BTZ), a proteasome inhibitor that promotes lipid accumulation. Subtoxic doses of ITF3756 and BTZ exerted a synergistic apoptotic effect in HCT116 cells and caused mTOR phosphorylation, SREBP activation and PPARg increase, thus enhancing lipid production. The ITF3756\/BTZ combination was less efficacious in HT29 cells that displayed a high basal level of lipid droplets. Diacylglycerol acyltransferase 1 (DGAT-1) and 2 (DGAT-2) inhibitors blocked lipogenesis and increased the effect of the ITF3756\/BTZ combination in both cell lines, thereby suggesting that lipogenesis represents a defensive response. This hypothesis was confirmed by SREBP-1 silencing, which also potentiated the antitumor efficacy of the ITF3756\/BTZ combination in HCT116 cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Overall, these results reveal a particular antitumor efficacy of the selective HDAC6 inhibitor in combination with BTZ in colon cancer cells and suggest that inhibiting lipogenesis is a useful tool to further increase the synergistic effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1706770","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T14:40:18Z","timestamp":1765550418000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting lipogenesis promotes the synergistic effect of the selective HDAC6 inhibitor ITF3756 with bortezomib in colon cancer cells"],"prefix":"10.3389","volume":"16","author":[{"given":"Marzia","family":"Franz\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zichittella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Di Liberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pratelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Affranchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Notaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Emanuele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"184-e366","DOI":"10.1002\/onco.13673","article-title":"First-in-class selective HDAC6 inhibitor (ACY-1215) has a highly favorable safety profile in patients with relapsed and refractory lymphoma","volume":"26","author":"Amengual","year":"2021","journal-title":"Oncologist"},{"key":"B2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.trecan.2020.10.004","article-title":"Fat and furious: lipid metabolism in antitumoral therapy response and resistance","volume":"7","author":"Bacci","year":"2021","journal-title":"Trends Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s43018-025-01004-2","article-title":"Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and\/or metastatic squamous cell carcinomas: a phase 2 basket trial","volume":"6","author":"Borcoman","year":"2025","journal-title":"Nat. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.clml.2020.11.019","article-title":"Bortezomib, vorinostat, and dexamethasone combination therapy in relapsed myeloma: results of the phase 2 MUK four trial","volume":"21","author":"Brown","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.bbrc.2023.06.015","article-title":"Combination treatment of bortezomib and epirubicin increases the expression of TNFRSF10 A\/B, and induces TRAIL-mediated cell death in colorectal cancer cells","volume":"675","author":"Caldiran","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/jcp.24863","article-title":"The synergistic effect of SAHA and parthenolide in MDA-MB231 breast cancer cells","volume":"230","author":"Carlisi","year":"2015","journal-title":"J. Cell Physiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.3390\/biomedicines10081994","article-title":"The histone deacetylase inhibitor ITF2357 (Givinostat) targets oncogenic BRAF in melanoma cells and promotes a switch from pro-survival autophagy to apoptosis","volume":"10","author":"Celesia","year":"","journal-title":"Biomedicines"},{"key":"B8","doi-asserted-by":"publisher","first-page":"120929","DOI":"10.1016\/j.ica.2022.120929","article-title":"Bortezomib potentiates the antitumor effect of tributyltin(IV) ferulate in colon cancer cells exacerbating ER stress and promoting apoptosis","volume":"537","author":"Celesia","year":"","journal-title":"Inorganica Chim. Acta"},{"key":"B9","doi-asserted-by":"publisher","first-page":"9148","DOI":"10.3390\/ijms24119148","article-title":"Oncogenic BRAF and p53 interplay in melanoma cells and the effects of the HDAC inhibitor ITF2357 (givinostat)","volume":"24","author":"Celesia","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2815187","DOI":"10.1155\/2022\/2815187","article-title":"HDAC8 promotes liver metastasis of colorectal cancer via inhibition of IRF1 and upregulation of SUCNR1","volume":"2022","author":"Chen","year":"2022","journal-title":"Oxid. Med. Cell Longev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40880-018-0301-4","article-title":"Lipid metabolism reprogramming and its potential targets in cancer","volume":"38","author":"Cheng","year":"","journal-title":"Cancer Commun. (Lond)."},{"key":"B12","doi-asserted-by":"publisher","first-page":"484","DOI":"10.2174\/1568026618666180523104541","article-title":"SCAP\/SREBPs are central players in lipid metabolism and novel metabolic targets in cancer therapy","volume":"18","author":"Cheng","year":"","journal-title":"Curr. Top. Med. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1805257","DOI":"10.1080\/23723556.2020.1805257","article-title":"DGAT1 protects tumor from lipotoxicity, emerging as a promising metabolic target for cancer therapy","volume":"7","author":"Cheng","year":"2020","journal-title":"Mol. Cell Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12967-024-05084-z","article-title":"The role of DGAT1 and DGAT2 in regulating tumor cell growth and their potential clinical implications","volume":"22","author":"Deng","year":"2024","journal-title":"J. Transl. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.biochi.2021.04.011","article-title":"Odd-chain fatty acids as novel histone deacetylase 6 (HDAC6) inhibitors","volume":"186","author":"Ediriweera","year":"2021","journal-title":"Biochimie"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1007\/s10637-022-01306-7","article-title":"TRIM59 guards ER proteostasis and prevents Bortezomib-mediated colorectal cancer (CRC) cells\u2019 killing","volume":"40","author":"Feng","year":"2022","journal-title":"Invest New Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2119\/molmed.2011.00020","article-title":"Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat)","volume":"17","author":"Furlan","year":"2011","journal-title":"Mol. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00277-009-0793-8","article-title":"A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma","volume":"89","author":"Galli","year":"2010","journal-title":"Ann. Hematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3324\/haematol.2023.283002","article-title":"Results from a phase I trial of pembrolizumab plus vorinostat in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"109","author":"Godfrey","year":"2024","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"publisher","first-page":"100987","DOI":"10.1016\/j.gendis.2023.04.022","article-title":"The roles and mechanisms of SREBP1 in cancer development and drug response","volume":"11","author":"He","year":"2024","journal-title":"Genes Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"12993","DOI":"10.2147\/CMAR.S284199","article-title":"Upregulated histone deacetylase 6 associates with malignant progression of melanoma and predicts the prognosis of patients","volume":"12","author":"Hu","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fonc.2019.00249","article-title":"MPT0G413, A novel HDAC6-Selective inhibitor, and bortezomib synergistically exert anti-tumor activity in multiple myeloma cells","volume":"9","author":"Huang","year":"2019","journal-title":"Front. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"117218","DOI":"10.1016\/j.biopha.2024.117218","article-title":"Small molecules targeting HDAC6 for cancer treatment: current progress and novel strategies","volume":"178","author":"Huang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"B25","doi-asserted-by":"publisher","first-page":"28237","DOI":"10.1074\/jbc.M114.571190","article-title":"Diacylglycerol acyltransferase-2 (DGAT2) and monoacylglycerol acyltransferase-2 (MGAT2) interact to promote triacylglycerol synthesis","volume":"289","author":"Jin","year":"2014","journal-title":"J. Biol. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12032-024-02303-x","article-title":"Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator","volume":"41","author":"Karati","year":"2024","journal-title":"Med. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1399065","DOI":"10.3389\/fcell.2024.1399065","article-title":"Unraveling the intricate relationship between lipid metabolism and oncogenic signaling pathways","volume":"12","author":"Khan","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"8645","DOI":"10.3390\/ijms23158645","article-title":"HDAC8-Selective inhibition by PCI-34051 enhances the anticancer effects of ACY-241 in ovarian cancer cells","volume":"23","author":"Kim","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1007\/s00277-024-05691-2","article-title":"A real-world pharmacovigilance study investigating the toxicities of histone deacetylase inhibitors","volume":"103","author":"Li","year":"2024","journal-title":"Ann. Hematol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12967-015-0753-0","article-title":"Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells","volume":"14","author":"Liu","year":"2016","journal-title":"J. Transl. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1039\/d3bm00254c","article-title":"Bortezomib-loaded mixed micelles realize a \u201cthree-in-one\u201d effect for enhanced breast cancer treatment","volume":"11","author":"Liu","year":"2023","journal-title":"Biomater. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2024.12.10.627820","DOI":"10.1101\/2024.12.10.627820","article-title":"HDAC6-Mediated FoxO1 acetylation and phosphorylation control periodontal inflammatory responses","author":"Lohner","year":"2024","journal-title":"BioRxiv"},{"key":"B33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/procel\/pwad038","article-title":"Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids","volume":"15","author":"Mao","year":"2024","journal-title":"Protein Cell"},{"key":"B34","doi-asserted-by":"publisher","first-page":"288","DOI":"10.29252\/ibj.24.5.283","article-title":"Association of HDAC8 expression with pathological findings in triple negative and non-triple negative breast cancer: implications for diagnosis","volume":"24","author":"Menbari","year":"2020","journal-title":"Iran. Biomed. J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3892\/ijo.2014.2441","article-title":"Lipogenesis in cancer progression (review)","volume":"45","author":"Mounier","year":"2014","journal-title":"Int. J. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.freeradbiomed.2017.01.007","article-title":"ATG14 facilitated lipophagy in cancer cells induce ER stress mediated mitoptosis through a ROS dependent pathway","volume":"104","author":"Mukhopadhyay","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00280-024-04731-y","article-title":"WT161, a selective HDAC6 inhibitor, decreases growth, enhances chemosensitivity, promotes apoptosis, and suppresses motility of melanoma cells","volume":"95","author":"Oliveira-Silva","year":"","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2174\/0115680096332732241113053459","article-title":"HDAC6: tumor progression and beyond","author":"Oliveira-Silva","year":"","journal-title":"Curr. Cancer Drug Targets"},{"key":"B39","doi-asserted-by":"publisher","first-page":"809382","DOI":"10.3389\/fcell.2021.809382","article-title":"Short-chain fatty acid butyrate induces cilia formation and potentiates the effects of HDAC6 inhibitors in cholangiocarcinoma cells","volume":"9","author":"Pant","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"4526","DOI":"10.3892\/ol.2018.9233","article-title":"Sequential treatment with celecoxib and bortezomib enhances the ER stress-mediated autophagy-associated cell death of colon cancer cells","volume":"16","author":"Park","year":"2018","journal-title":"Oncol. Lett."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s12272-020-01281-8","article-title":"Ubiquitin-proteasome system (UPS) as a target for anticancer treatment","volume":"43","author":"Park","year":"2020","journal-title":"Arch. Pharm. Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.2174\/0929867329666220922105615","article-title":"Multi-targeted HDAC inhibitors as anticancer agents: current status and future prospective","volume":"30","author":"Patel","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3892\/or.2016.5340","article-title":"ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation","volume":"37","author":"Peng","year":"2017","journal-title":"Oncol. Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e70725","DOI":"10.1002\/cam4.70725","article-title":"A phase I\/IB, open label, dose finding study to evaluate safety, pharmacodynamics and efficacy of pembrolizumab in combination with vorinostat in patients with advanced prostate, renal or urothelial carcinoma","volume":"14","author":"Pili","year":"2025","journal-title":"Cancer Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"105274","DOI":"10.1016\/j.phrs.2020.105274","article-title":"HDAC6 as privileged target in drug discovery: a perspective","volume":"163","author":"Pulya","year":"2021","journal-title":"Pharmacol. Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1172\/JCI85963","article-title":"HDAC6-mediated acetylation of lipid droplet-binding protein CIDEC regulates fat-induced lipid storage","volume":"127","author":"Qian","year":"2017","journal-title":"J. Clin. Invest"},{"key":"B47","doi-asserted-by":"publisher","first-page":"102521","DOI":"10.1016\/j.pdpdt.2021.102521","article-title":"Indocyanine green loaded pH-responsive bortezomib supramolecular hydrogel for synergistic chemo-photothermal\/photodynamic colorectal cancer therapy","volume":"36","author":"Qing","year":"2021","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"119504","DOI":"10.1016\/j.lfs.2021.119504","article-title":"Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy","volume":"277","author":"Ramaiah","year":"2021","journal-title":"Life Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br. J. Haematol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.3390\/cancers14153714","article-title":"Reprogrammed lipid metabolism and the lipid-associated hallmarks of colorectal cancer","volume":"14","author":"Salita","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1021\/acsmedchemlett.1c00425","article-title":"Role of fluorination in the histone deacetylase 6 (HDAC6) selectivity of benzohydroxamate-based inhibitors","volume":"12","author":"Sandrone","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"B52","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.canlet.2021.05.012","article-title":"E2F1 promotes proliferation and metastasis of clear cell renal cell carcinoma via activation of SREBP1-dependent fatty acid biosynthesis","volume":"514","author":"Shen","year":"2021","journal-title":"Cancer Lett."},{"key":"B53","doi-asserted-by":"publisher","first-page":"123125","DOI":"10.1016\/j.lfs.2024.123125","article-title":"Bortezomib in cancer therapy: mechanisms, side effects, and future proteasome inhibitors","volume":"358","author":"Sogbein","year":"2024","journal-title":"Life Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1546939","DOI":"10.3389\/fimmu.2025.1546939","article-title":"HDAC6 inhibition by ITF3756 modulates PD-L1 expression and monocyte phenotype: insights for a promising immune checkpoint blockade co-treatment therapy","volume":"16","author":"Spadotto","year":"2025","journal-title":"Front. Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e31619","DOI":"10.1002\/pbc.31619","article-title":"Phase I study of vorinostat and temsirolimus in newly diagnosed or progressive diffuse intrinsic pontine glioma","volume":"72","author":"Stitzlein","year":"2025","journal-title":"Pediatr. Blood Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e19235","DOI":"10.7717\/peerj.19235","article-title":"Effects of bortezomib on intracellular antioxidant and apoptosis in HepG2cells","volume":"13","author":"Swiderska-Kolacz","year":"2025","journal-title":"PeerJ"},{"key":"B57","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.3390\/ijms23137283","article-title":"Targeting the SREBP-1\/Hsa-Mir-497\/SCAP\/FASN oncometabolic axis inhibits the cancer stem-like and chemoresistant phenotype of non-small cell lung carcinoma cells","volume":"23","author":"Tiong","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"10711","DOI":"10.1021\/acs.jmedchem.9b01194","article-title":"Novel benzohydroxamate-based potent and selective histone deacetylase 6 (HDAC6) inhibitors bearing a pentaheterocyclic scaffold: design, synthesis, and biological evaluation","volume":"62","author":"Vergani","year":"2019","journal-title":"J. Med. Chem."},{"key":"B59","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/pharmaceutics16010054","article-title":"Role of histone deacetylase 6 and histone deacetylase 6 inhibition in colorectal cancer","volume":"16","author":"Vuletic","year":"2023","journal-title":"Pharmaceutics"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.3892\/ol.2020.11853","article-title":"SREBP1 silencing inhibits the proliferation and motility of human esophageal squamous carcinoma cells via the Wnt\/beta-catenin signaling pathway","volume":"20","author":"Wang","year":"2020","journal-title":"Oncol. Lett."},{"key":"B61","doi-asserted-by":"publisher","first-page":"134835","DOI":"10.1016\/j.ijbiomac.2024.134835","article-title":"The role of DGAT1 and DGAT2 in tumor progression via fatty acid metabolism: a comprehensive review","volume":"278","author":"Wang","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/mc.22852","article-title":"A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells","volume":"57","author":"Won","year":"2018","journal-title":"Mol. Carcinog."},{"key":"B63","doi-asserted-by":"publisher","first-page":"6255","DOI":"10.18632\/oncotarget.6669","article-title":"Fast clearance of lipid droplets through MAP1S-activated autophagy suppresses clear cell renal cell carcinomas and promotes patient survival","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"B64","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1111\/bph.15653","article-title":"Targeting lipid metabolism in multiple myeloma cells: rational development of a synergistic strategy with proteasome inhibitors","volume":"178","author":"Xu","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.7150\/thno.82920","article-title":"The role of lipid metabolic reprogramming in tumor microenvironment","volume":"13","author":"Yang","year":"2023","journal-title":"Theranostics"},{"key":"B66","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13148-024-01725-8","article-title":"HDAC6 inhibition disrupts HDAC6-P300 interaction reshaping the cancer chromatin landscape","volume":"16","author":"Zamperla","year":"2024","journal-title":"Clin. Epigenetics"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.2147\/OTT.S194986","article-title":"Histone deacetylase 6 is overexpressed and promotes tumor growth of colon cancer through regulation of the MAPK\/ERK signal pathway","volume":"12","author":"Zhang","year":"2019","journal-title":"Onco Targets Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"952371","DOI":"10.3389\/fonc.2022.952371","article-title":"Targeting SREBP-1-Mediated lipogenesis as potential strategies for cancer","volume":"12","author":"Zhao","year":"2022","journal-title":"Front. Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3892\/etm.2015.2617","article-title":"Bortezomib inhibits cell proliferation in prostate cancer","volume":"10","author":"Zheng","year":"2015","journal-title":"Exp. Ther. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"123219","DOI":"10.1016\/j.ijbiomac.2023.123219","article-title":"Curriculum vitae of HDAC6 in solid tumors","volume":"230","author":"Zheng","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s42003-025-07918-y","article-title":"IL-27 alleviates high-fat diet-induced obesity and metabolic disorders by inhibiting adipogenesis via activating HDAC6","volume":"8","author":"Zhong","year":"2025","journal-title":"Commun. Biol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1186\/s12885-022-09666-2","article-title":"Mir-675-5p supports hypoxia-induced drug resistance in colorectal cancer cells","volume":"22","author":"Zichittella","year":"2022","journal-title":"BMC Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1275833","DOI":"10.3389\/fphar.2023.1275833","article-title":"Long non-coding RNA H19 enhances the pro-apoptotic activity of ITF2357 (a histone deacetylase inhibitor) in colorectal cancer cells","volume":"14","author":"Zichittella","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1706770\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T14:40:19Z","timestamp":1765550419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1706770\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":73,"alternative-id":["10.3389\/fphar.2025.1706770"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1706770","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"article-number":"1706770"}}